Canada Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Active Pharmaceutical Ingredient CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the active pharmaceutical ingredient cdmo market
Canada active pharmaceutical ingredient cdmo market highlights
- The Canada active pharmaceutical ingredient cdmo market generated a revenue of USD 2,876.1 million in 2025 and is expected to reach USD 4,668.0 million by 2033.
- The Canada market is expected to grow at a CAGR of 6.4% from 2026 to 2033.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2025.
- Antibody Drug Conjugate (ADC) is the most lucrative product segment registering the fastest growth during the forecast period.
Active pharmaceutical ingredient cdmo market data book summary
| Market revenue in 2025 | USD 2,876.1 million |
| Market revenue in 2033 | USD 4,668.0 million |
| Growth rate | 6.4% (CAGR from 2026 to 2033) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibody Drug Conjugate (ADC), Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API) |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, Canada accounted for 2.5% of the global active pharmaceutical ingredient cdmo market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 72,649.3 million by 2033.
Canada accounted for 2.5% of North America’s market in 2020. Its regulatory environment is governed by Health Canada. Presence of a well-established healthcare system and favorable government support are expected to boost the market.
Growing number of clinical trials in the country also creates opportunities for active pharmaceutical ingredient CDMOs. For instance, according to WHO ICTRP, 30,138 clinical trials were conducted in Canada between 1999 and 2020.
Increasing investments in CDMOs in the country are anticipated to propel the market. For instance, in January 2020, Piramal Pharma Solutions, an Indian pharmaceutical firm, invested nearly USD 17 million (CAD 25 million) in its Aurora-based facility to establish a new API manufacturing unit.
No credit card required*
Publish Date: Sep 16, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | www.recipharm.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
Canada Active Pharmaceutical Ingredient CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Active Pharmaceutical Ingredient CDMO Market Outlook will help companies and investors design strategic landscapes.
Traditional Active Pharmaceutical Ingredient (Traditional Api) was the largest segment with a revenue share of 46.28% in 2025.
Horizon Databook has segmented the Canada active pharmaceutical ingredient cdmo market based on antibody drug conjugate (adc), traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api) covering the revenue growth of each sub-segment from 2021 to 2033.
Canada accounted for 2.5% of North America’s market in 2020. Its regulatory environment is governed by Health Canada. Presence of a well-established healthcare system and favorable government support are expected to boost the market.
Growing number of clinical trials in the country also creates opportunities for active pharmaceutical ingredient CDMOs. For instance, according to WHO ICTRP, 30,138 clinical trials were conducted in Canada between 1999 and 2020.
Increasing investments in CDMOs in the country are anticipated to propel the market. For instance, in January 2020, Piramal Pharma Solutions, an Indian pharmaceutical firm, invested nearly USD 17 million (CAD 25 million) in its Aurora-based facility to establish a new API manufacturing unit.
- Canada Active Pharmaceutical Ingredient Cdmo Market Product Outlook (Revenue, USD Million , 2021-2033)
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC
- Others
- Canada Active Pharmaceutical Ingredient Cdmo Market Synthesis Outlook (Revenue, USD Million , 2021-2033)
- Synthetic
- Biotech
- Canada Active Pharmaceutical Ingredient Cdmo Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Innovative
- Generics
- Canada Active Pharmaceutical Ingredient Cdmo Market Workflow Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- Canada Active Pharmaceutical Ingredient Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular disease
- Diabetes
- Others
Reasons to subscribe to Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Our clientele includes a mix of Active Pharmaceutical Ingredient CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Active Pharmaceutical Ingredient CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Active Pharmaceutical Ingredient CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Canada Active Pharmaceutical Ingredient Cdmo Market, 2021-2033 (US$M)
Canada active pharmaceutical ingredient cdmo market statistics, by product, 2021-2033 (US$M)
